Føroya Banki (previously BankNordik) will publish its Q1 2024 report on 2 May.
Scanfil’s Q1 revenue fell more than estimated, which also caused EBIT to drop below estimates, howev...
Redeye is making some downward adjustments to our financial forecasts following the Q1 report.
37% premium to date of strategic review, 8% discount to last close Equates to '24e-'26e EV/ARR of 4.
'24e-'26e sales up 2-1% Volume growth to continue into the year FVR of SEK 20-35 reiterated Q1: Str...
We cut '24e-'26e sales by 7-10% Sominis divestment weighs on est.
Tough comps, we expect -3% org sales growth (119% Q1'23) The Intercom order behind 2024e estimate ch...
-4% organisk tillväxt kompenseras av Thebalux-förvärvet Med höga jämförelsetal och fortsatt svår mar...
Tumorad is in clinical phase 1, and today, Spago Nanomedical announced that Tumorad had promising re...
- Q1e: sales +41% y-o-y, ~10% EBIT margin (SDR now consolidated) - Raising '24e EPS by 22% on huge u...
Redeye comments on Truecaller’s newly proposed dividend policy, which we believe de-risks the case w...
Redeye provides a research update following Lipum’s clinical progress, recent rights issue, and revi...
XVIVO improved its organic growth to 32% compared with the unusually modest 12% level in Q4 2023.
Calliditas confirms that the OLE (Open Label Extension study) treatment response is consistent with ...
Finnair’s Q1 revenue was a bit soft relative to estimates, however earnings were as estimated thanks...
Scanfil’s Q1 results were expected to be soft relative to the comparison period but still came in so...
Spain's largest grocery retailer commits to StrongPoint Large market potential - EUR 250m in spain a...
Emission avslutad Diamyd meddelade under föregående vecka utfallet av sin företrädesemission.
Maven Wireless kommunicerade den 23 april att bolaget har ingått ett produktionsavtal med Vexos Inc.
Organic growth of 79%, +34pp above ABGSCe Paying users 6% above ABGSCe Likely positive cons.
